Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.84
NYSE:AGN's Cash to Debt is ranked lower than
61% of the 789 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. NYSE:AGN: 0.84 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:AGN' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.44 Max: 43.62
Current: 0.84
0.01
43.62
Equity to Asset 0.63
NYSE:AGN's Equity to Asset is ranked higher than
50% of the 722 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. NYSE:AGN: 0.63 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:AGN' s Equity to Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.6 Max: 0.9
Current: 0.63
0.25
0.9
F-Score: 7
Z-Score: 1.26
M-Score: -1.94
WACC vs ROIC
7.89%
-0.82%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -7.96
NYSE:AGN's Operating margin (%) is ranked lower than
78% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.25 vs. NYSE:AGN: -7.96 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:AGN' s Operating margin (%) Range Over the Past 10 Years
Min: -36.27  Med: 6.95 Max: 14.13
Current: -7.96
-36.27
14.13
Net-margin (%) 83.91
NYSE:AGN's Net-margin (%) is ranked higher than
99% of the 737 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. NYSE:AGN: 83.91 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:AGN' s Net-margin (%) Range Over the Past 10 Years
Min: -28.83  Med: 5.41 Max: 83.91
Current: 83.91
-28.83
83.91
ROE (%) 17.67
NYSE:AGN's ROE (%) is ranked higher than
80% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.55 vs. NYSE:AGN: 17.67 )
Ranked among companies with meaningful ROE (%) only.
NYSE:AGN' s ROE (%) Range Over the Past 10 Years
Min: -23.54  Med: 6.44 Max: 17.67
Current: 17.67
-23.54
17.67
ROA (%) 10.38
NYSE:AGN's ROA (%) is ranked higher than
80% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. NYSE:AGN: 10.38 )
Ranked among companies with meaningful ROA (%) only.
NYSE:AGN' s ROA (%) Range Over the Past 10 Years
Min: -13.02  Med: 3.54 Max: 10.38
Current: 10.38
-13.02
10.38
ROC (Joel Greenblatt) (%) -26.72
NYSE:AGN's ROC (Joel Greenblatt) (%) is ranked lower than
77% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.88 vs. NYSE:AGN: -26.72 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:AGN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -113.61  Med: 20.42 Max: 38.44
Current: -26.72
-113.61
38.44
Revenue Growth (3Y)(%) -3.80
NYSE:AGN's Revenue Growth (3Y)(%) is ranked lower than
75% of the 609 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.20 vs. NYSE:AGN: -3.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:AGN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -14  Med: 16.2 Max: 40.4
Current: -3.8
-14
40.4
EBITDA Growth (3Y)(%) 1.00
NYSE:AGN's EBITDA Growth (3Y)(%) is ranked lower than
65% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.60 vs. NYSE:AGN: 1.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:AGN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -39.9  Med: 3.6 Max: 33.2
Current: 1
-39.9
33.2
» NYSE:AGN's 10-Y Financials

Financials (Next Earnings Date: Est. 2017-08-08)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

AGN Guru Trades in Q4 2015

John Hussman 5,000 sh (New)
David Tepper 150,000 sh (New)
Steven Cohen 73,200 sh (New)
Eric Mindich 948,569 sh (New)
Louis Moore Bacon 6,816 sh (New)
Ron Baron 11,752 sh (New)
David Einhorn 410,000 sh (New)
Joel Greenblatt 42,240 sh (New)
Paul Tudor Jones 50,857 sh (+349.39%)
Jim Simons 206,701 sh (+283.00%)
Paul Singer 2,020,500 sh (+204.75%)
Daniel Loeb 5,400,000 sh (+47.18%)
John Griffin 2,000,000 sh (+22.64%)
Vanguard Health Care Fund 10,962,347 sh (+19.27%)
Alan Fournier 765,800 sh (+17.44%)
Lee Ainslie 679,930 sh (+17.14%)
Mario Gabelli 33,473 sh (+5.06%)
Wallace Weitz 196,170 sh (+4.56%)
Ken Fisher 3,306 sh (+3.80%)
Paul Tudor Jones 20,000 sh (unchged)
Paul Singer 770,000 sh (unchged)
Bernard Horn 20,689 sh (unchged)
David Carlson 340,000 sh (unchged)
Samuel Isaly 343,025 sh (unchged)
Chris Davis Sold Out
Dodge & Cox Sold Out
Kyle Bass Sold Out
Julian Robertson Sold Out
Steve Mandel Sold Out
Larry Robbins Sold Out
RS Investment Management 352,778 sh (-1.57%)
Ruane Cunniff 1,085,870 sh (-1.59%)
Private Capital 166,017 sh (-2.12%)
Leon Cooperman 781,780 sh (-3.68%)
Pioneer Investments 632,600 sh (-8.71%)
Diamond Hill Capital 57,154 sh (-14.43%)
Andreas Halvorsen 5,978,075 sh (-17.00%)
First Pacific Advisors 24,100 sh (-21.19%)
John Paulson 5,532,600 sh (-22.97%)
Jana Partners 1,164,663 sh (-38.28%)
George Soros 365,390 sh (-52.83%)
First Eagle Investment 669,995 sh (-59.91%)
Jeremy Grantham 281,993 sh (-65.60%)
Scott Black 7,453 sh (-80.39%)
» More
Q1 2016

AGN Guru Trades in Q1 2016

Jerome Dodson 40,000 sh (New)
Seth Klarman 1,721,587 sh (New)
Steve Mandel 1,789,239 sh (New)
Ron Baron 27,278 sh (+132.11%)
Lee Ainslie 1,410,362 sh (+107.43%)
Eric Mindich 1,875,073 sh (+97.67%)
Paul Tudor Jones 100,489 sh (+97.59%)
David Tepper 279,109 sh (+86.07%)
Wallace Weitz 304,722 sh (+55.34%)
Paul Singer 2,497,051 sh (+23.59%)
Mario Gabelli 39,798 sh (+18.90%)
Pioneer Investments 700,680 sh (+10.76%)
David Carlson 370,000 sh (+8.82%)
David Einhorn 437,200 sh (+6.63%)
Diamond Hill Capital 60,724 sh (+6.25%)
Vanguard Health Care Fund 11,187,547 sh (+2.05%)
John Hussman 5,000 sh (unchged)
Alan Fournier 500,000 sh (unchged)
Paul Tudor Jones 140,000 sh (unchged)
Paul Singer 770,000 sh (unchged)
John Paulson 214,700 sh (unchged)
Jim Simons Sold Out
Louis Moore Bacon Sold Out
First Pacific Advisors Sold Out
Steven Cohen Sold Out
John Paulson 5,418,300 sh (-2.07%)
Ken Fisher 3,225 sh (-2.45%)
Private Capital 161,728 sh (-2.58%)
Signature Select Canadian Fund 34,300 sh (-3.11%)
Ruane Cunniff 1,025,555 sh (-5.55%)
RS Investment Management 330,590 sh (-6.29%)
Daniel Loeb 5,000,000 sh (-7.41%)
Bernard Horn 17,389 sh (-15.95%)
Andreas Halvorsen 4,881,957 sh (-18.34%)
John Griffin 1,502,700 sh (-24.87%)
Leon Cooperman 561,265 sh (-28.21%)
Jeremy Grantham 188,267 sh (-33.24%)
Scott Black 4,905 sh (-34.19%)
Alan Fournier 500,000 sh (-34.71%)
First Eagle Investment 371,770 sh (-44.51%)
George Soros 143,277 sh (-60.79%)
Jana Partners 446,893 sh (-61.63%)
Joel Greenblatt 14,367 sh (-65.99%)
Samuel Isaly 341,025 sh (-0.58%)
» More
Q2 2016

AGN Guru Trades in Q2 2016

Jeff Auxier 1,050 sh (New)
John Burbank 708,071 sh (New)
Robert Bruce 25,000 sh (New)
Carl Icahn 3,400,000 sh (New)
David Tepper 1,260,809 sh (+351.73%)
Jerome Dodson 102,000 sh (+155.00%)
Alan Fournier 1,171,614 sh (+134.32%)
Wallace Weitz 595,961 sh (+95.58%)
Mario Gabelli 60,913 sh (+53.06%)
RS Investment Management 489,611 sh (+48.10%)
Joel Greenblatt 20,529 sh (+42.89%)
Scott Black 6,365 sh (+29.77%)
Pioneer Investments 888,950 sh (+26.87%)
Leon Cooperman 671,212 sh (+19.59%)
Seth Klarman 2,001,978 sh (+16.29%)
David Carlson 430,000 sh (+16.22%)
Ken Fisher 3,594 sh (+11.44%)
Paul Singer 2,735,000 sh (+9.53%)
Vanguard Health Care Fund 12,066,307 sh (+7.85%)
Diamond Hill Capital 62,502 sh (+2.93%)
Daniel Loeb 500,000 sh (unchged)
John Burbank 90,000 sh (unchged)
Alan Fournier 1,100,000 sh (unchged)
Louis Moore Bacon 12,000 sh (unchged)
Paul Singer 3,000,300 sh (unchged)
John Paulson 214,700 sh (unchged)
Bernard Horn 17,389 sh (unchged)
John Hussman Sold Out
First Eagle Investment Sold Out
Jeremy Grantham Sold Out
Jana Partners Sold Out
Eric Mindich Sold Out
Steve Mandel Sold Out
David Einhorn Sold Out
Daniel Loeb 4,900,000 sh (-2.00%)
Private Capital 137,319 sh (-15.09%)
John Paulson 3,948,451 sh (-27.13%)
Lee Ainslie 878,319 sh (-37.72%)
George Soros 80,735 sh (-43.65%)
Ron Baron 13,923 sh (-48.96%)
John Griffin 700,900 sh (-53.36%)
Andreas Halvorsen 1,939,703 sh (-60.27%)
Paul Tudor Jones 34,942 sh (-65.23%)
Ruane Cunniff 3,435 sh (-99.67%)
Samuel Isaly 273,025 sh (-19.94%)
» More
Q3 2016

AGN Guru Trades in Q3 2016

Manning & Napier Advisors, Inc 10,510 sh (New)
Tom Gayner 2,000 sh (New)
Jeff Auxier 6,750 sh (+542.86%)
John Griffin 1,259,200 sh (+79.65%)
Ron Baron 17,109 sh (+22.88%)
Ken Fisher 4,024 sh (+11.96%)
Pioneer Investments 982,212 sh (+10.49%)
David Carlson 450,000 sh (+4.65%)
Jerome Dodson 104,500 sh (+2.45%)
Wallace Weitz 609,963 sh (+2.35%)
Scott Black 6,405 sh (+0.63%)
Samuel Isaly 350,880 sh (+28.52%)
Louis Moore Bacon 12,000 sh (unchged)
Alan Fournier 1,100,000 sh (unchged)
Seth Klarman 2,001,978 sh (unchged)
Paul Singer 2,735,000 sh (unchged)
Paul Singer 2,099,700 sh (unchged)
George Soros 80,735 sh (unchged)
John Paulson 214,700 sh (unchged)
Robert Bruce 25,000 sh (unchged)
Bernard Horn 17,389 sh (unchged)
Lee Ainslie Sold Out
Andreas Halvorsen Sold Out
Joel Greenblatt Sold Out
Vanguard Health Care Fund 11,917,739 sh (-1.23%)
John Paulson 3,891,134 sh (-1.45%)
Private Capital 134,667 sh (-1.93%)
David Tepper 1,218,309 sh (-3.37%)
Mario Gabelli 55,988 sh (-8.09%)
Ruane Cunniff 3,075 sh (-10.48%)
Diamond Hill Capital 52,179 sh (-16.52%)
Leon Cooperman 541,122 sh (-19.38%)
Paul Tudor Jones 27,428 sh (-21.50%)
Daniel Loeb 3,785,000 sh (-22.76%)
Alan Fournier 621,214 sh (-46.98%)
John Burbank 375,134 sh (-47.02%)
Carl Icahn 425,438 sh (-87.49%)
» More
» Details

Insider Trades

Latest Guru Trades with AGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Allergan PLC

SymbolPriceYieldDescription
AGNPRA711.847.875 1/2 % Cum.Conv.Pref.Shs 2015-1.3.18 Series -A-

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412 
Compare:NYSE:TEVA, OTCPK:TKPYY, NYSE:ZTS, NAS:MYL, OTCPK:ESALY, OTCPK:SGIOF, OTCPK:MKGAY, NYSE:PRGO, OTCPK:MTZPY, OTCPK:ITHUF, OTCPK:APNHY, NYSE:RDY, OTCPK:SFOSF, OTCPK:HLUYY, NYSE:MNK, NAS:OPK, NYSE:VRX, OTCPK:IPSEY, OTCPK:HYPMY, OTCPK:HKMPF » details
Traded in other countries:A60.Germany, AGN N.Mexico,
Allergan PLC is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and distributing generic, brand and biosimilar products.

Allergan PLC, formerly known as Actavis PLC was incorporated in Ireland on May 16, 2013. It is an integrated specialty pharmaceutical company. The Company is engaged in development, manufacturing, marketing, sale and distribution of generic, branded generic, brand name, biosimilar and over-the-counter pharmaceutical products. It also develops and out-license generic pharmaceutical products in Europe through its Medis third-party business. It operates in three segments, Pharma, Specialty Brands and Anda Distribution. The Pharma segment includes off-patent pharmaceutical products that are therapeutically equivalent to proprietary products. The Specialty Brands segment includes patent-protected products and certain trademarked off-patent products that the Company sells and markets as brand pharmaceutical products. The Anda Distribution segment distributes generic and brand pharmaceutical products manufactured by third parties, as well as by the Company to independent pharmacies, pharmacy chains, pharmacy buying groups and physicians' offices. It competes with generic manufacturers of pharmaceutical products. It is subject to extensive, complex and evolving regulation by the federal government, the FDA, and to a lesser extent, by the U.S. Drug Enforcement Administration Occupational Safety and Health Administration and state government agencies, as well as by various regulatory agencies in foreign countries where its products or product candidates are being manufactured and/or marketed. The Federal Food, Drug and Cosmetic Act, the Controlled Substances Act and other federal statutes and regulations govern or influence the testing, manufacturing, packing, labeling, storing, record keeping, safety, approval, advertising, promotion, sale and distribution of its products.

Ratios

vs
industry
vs
history
P/E(ttm) 5.39
AGN's P/E(ttm) is ranked higher than
96% of the 537 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.49 vs. AGN: 5.39 )
Ranked among companies with meaningful P/E(ttm) only.
AGN' s P/E(ttm) Range Over the Past 10 Years
Min: 5.2  Med: 25.82 Max: 366.63
Current: 5.39
5.2
366.63
Forward P/E 11.79
AGN's Forward P/E is ranked higher than
70% of the 63 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.41 vs. AGN: 11.79 )
Ranked among companies with meaningful Forward P/E only.
N/A
Price/Owner Earnings (ttm) 3.84
AGN's Price/Owner Earnings (ttm) is ranked higher than
95% of the 280 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.53 vs. AGN: 3.84 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
AGN' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 3.72  Med: 18.88 Max: 1279.04
Current: 3.84
3.72
1279.04
P/B 0.90
AGN's P/B is ranked higher than
88% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. AGN: 0.90 )
Ranked among companies with meaningful P/B only.
AGN' s P/B Range Over the Past 10 Years
Min: 0.86  Med: 1.74 Max: 5.9
Current: 0.9
0.86
5.9
P/S 4.30
AGN's P/S is ranked lower than
63% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.85 vs. AGN: 4.30 )
Ranked among companies with meaningful P/S only.
AGN' s P/S Range Over the Past 10 Years
Min: 0.99  Med: 1.84 Max: 17.57
Current: 4.3
0.99
17.57
PFCF 27.58
AGN's PFCF is ranked lower than
59% of the 197 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.94 vs. AGN: 27.58 )
Ranked among companies with meaningful PFCF only.
AGN' s PFCF Range Over the Past 10 Years
Min: 6.62  Med: 15.16 Max: 36.71
Current: 27.58
6.62
36.71
POCF 23.87
AGN's POCF is ranked lower than
66% of the 268 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.41 vs. AGN: 23.87 )
Ranked among companies with meaningful POCF only.
AGN' s POCF Range Over the Past 10 Years
Min: 5.97  Med: 12.42 Max: 31.19
Current: 23.87
5.97
31.19
EV-to-EBITDA 15.15
AGN's EV-to-EBITDA is ranked higher than
59% of the 562 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.70 vs. AGN: 15.15 )
Ranked among companies with meaningful EV-to-EBITDA only.
AGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -224.1  Med: 11.1 Max: 386.1
Current: 15.15
-224.1
386.1
Shiller P/E 48.66
AGN's Shiller P/E is ranked lower than
52% of the 159 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.94 vs. AGN: 48.66 )
Ranked among companies with meaningful Shiller P/E only.
AGN' s Shiller P/E Range Over the Past 10 Years
Min: 19.13  Med: 53.29 Max: 2115.42
Current: 48.66
19.13
2115.42
Current Ratio 3.95
AGN's Current Ratio is ranked higher than
71% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. AGN: 3.95 )
Ranked among companies with meaningful Current Ratio only.
AGN' s Current Ratio Range Over the Past 10 Years
Min: 0.99  Med: 2.78 Max: 9.8
Current: 3.95
0.99
9.8
Quick Ratio 3.86
AGN's Quick Ratio is ranked higher than
76% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. AGN: 3.86 )
Ranked among companies with meaningful Quick Ratio only.
AGN' s Quick Ratio Range Over the Past 10 Years
Min: 0.78  Med: 1.92 Max: 8.82
Current: 3.86
0.78
8.82
Days Inventory 75.03
AGN's Days Inventory is ranked higher than
72% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.28 vs. AGN: 75.03 )
Ranked among companies with meaningful Days Inventory only.
AGN' s Days Inventory Range Over the Past 10 Years
Min: 66.09  Med: 121.54 Max: 369.82
Current: 75.03
66.09
369.82
Days Sales Outstanding 51.22
AGN's Days Sales Outstanding is ranked higher than
73% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.78 vs. AGN: 51.22 )
Ranked among companies with meaningful Days Sales Outstanding only.
AGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.05  Med: 63.94 Max: 197.04
Current: 51.22
39.05
197.04
Days Payable 24.73
AGN's Days Payable is ranked lower than
88% of the 571 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 71.88 vs. AGN: 24.73 )
Ranked among companies with meaningful Days Payable only.
AGN' s Days Payable Range Over the Past 10 Years
Min: 24.73  Med: 76.38 Max: 109.48
Current: 24.73
24.73
109.48

Buy Back

vs
industry
vs
history
Forward Dividend Yield 1.49
AGN's Forward Dividend Yield is ranked lower than
55% of the 646 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. AGN: 1.49 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 0.09
AGN's Yield on cost (5-Year) is ranked lower than
97% of the 791 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.10 vs. AGN: 0.09 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
AGN' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.08  Med: 0.32 Max: 0.63
Current: 0.09
0.08
0.63
3-Year Average Share Buyback Ratio -45.60
AGN's 3-Year Average Share Buyback Ratio is ranked lower than
92% of the 435 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.60 vs. AGN: -45.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -45.6  Med: -6 Max: 2
Current: -45.6
-45.6
2

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.87
AGN's Price/Projected FCF is ranked higher than
87% of the 307 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.77 vs. AGN: 0.87 )
Ranked among companies with meaningful Price/Projected FCF only.
AGN' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.6  Med: 1.17 Max: 3.29
Current: 0.87
0.6
3.29
Price/Median PS Value 2.35
AGN's Price/Median PS Value is ranked lower than
86% of the 615 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.14 vs. AGN: 2.35 )
Ranked among companies with meaningful Price/Median PS Value only.
AGN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.67  Med: 1.36 Max: 8.52
Current: 2.35
0.67
8.52
Earnings Yield (Greenblatt) (%) -1.38
AGN's Earnings Yield (Greenblatt) (%) is ranked lower than
73% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. AGN: -1.38 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AGN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -1.41  Med: 6.1 Max: 12.3
Current: -1.38
-1.41
12.3
Forward Rate of Return (Yacktman) (%) 4.74
AGN's Forward Rate of Return (Yacktman) (%) is ranked lower than
56% of the 344 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.15 vs. AGN: 4.74 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
AGN' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -5.2  Med: 7.4 Max: 16.1
Current: 4.74
-5.2
16.1

More Statistics

Revenue (TTM) (Mil) $17,093
EPS (TTM) $ 35.41
Beta1.20
Short Percentage of Float6.90%
52-Week Range $184.50 - 317.48
Shares Outstanding (Mil)374.95

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 14,519 15,499 16,791 17,941
EPS ($) 13.47 16.20 18.70 20.97
EPS w/o NRI ($) 13.47 16.20 18.70 20.97
EPS Growth Rate
(3Y to 5Y Estimate)
14.11%
Dividends Per Share ($) 1.40 1.87 1.54 3.39
» More Articles for NYSE:AGN

Headlines

Articles On GuruFocus.com
Teva Is a Hold Nov 30 2016 
Weekly CEO Buys Highlight Nov 29 2016 
Weekly Top Insider Buys Highlight for Week of Nov. 18 Nov 19 2016 
John Griffin Expands Portfolio in 3rd Quarter Nov 16 2016 
Weitz Funds Comments on Allergan Nov 11 2016 
Weitz Balanced Fund 3rd Quarter Commentary Nov 11 2016 
3 Health Industry Sectors Bound to Profit From a Trump Presidency Nov 11 2016 
Markel’s Tom Gayner Buys 4 Stocks During Quarter Nov 08 2016 
Buy Health Care Now? It All Depends on the Election Nov 07 2016 
Allergan: Trading at a Low Earnings Multiple Nov 06 2016 

More From Other Websites
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in... Dec 09 2016
Record-setting stock streak hits sixth day on broad gains Dec 09 2016
Allergan Unhappy with Patent Office Decision to Allow Mylan Challenge to Restasis Patents Dec 09 2016
Allergan Shares Are Up 4% After Analyst Comments Dec 09 2016
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Allergan... Dec 08 2016
Health care sector suffers: Time to buy the dip? Dec 08 2016
Allergan Talks Strategy at Citi Conference Dec 08 2016
3:42 pm Allergan announces the PTAB granted Mylan (MYL)'s... Dec 08 2016
Allergan Comments on PTAB Decision Regarding Mylan's Petitions for Inter Partes Review (IPR) of... Dec 08 2016
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against... Dec 08 2016
The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of... Dec 08 2016
DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And... Dec 07 2016
Biotech analyst: Republicans will protect drug companies from Trump Dec 07 2016
Teva Pharmaceutical Industries Ltd (ADR) (TEVA)’s End-Of-Year Switch Of Generics CEO Surprises... Dec 07 2016
Drug pressure deja vu? Dec 07 2016
Don't Expect Allergan To Rebound In 2017 Dec 07 2016
Piper Jaffray Negative On Allergan (AGN) Dec 07 2016
5 Best Large-Caps To Buy According To This Billionaire Dec 06 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)